Caredx reports preliminary financial results for third quarter 2024

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) — the transplant company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended september 30, 2024. third quarter 2024 highlights third quarter revenue is expected to be in the range of $82 million to $83 million, a.
CDNA Ratings Summary
CDNA Quant Ranking